ArticleTherapeutic advances in medical oncology2020
Opportunistic screening and survival prediction of digestive cancers by the combination of blood
Article in Therapeutic advances in medical oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 2 syntheses or guidelines pooled it, 26 citations in OpenAlex.
- Circulating tumor DNA and prognosis in gastric cancer patients undergoing surgery: meta-analysis and trial sequential analysis.Frontiers in oncology · 2026Pooled it
- Diagnostic accuracy of methylatedFrontiers in endocrinology · 2025Pooled it
- A scoping review of DNA methylation biomarkers for non-invasive detection of colorectal cancer at the CpG site level.Clinical epigenetics · 2026Article
- A liquid biopsy-based multi-methylation marker panel for minimally invasive gastric cancer screening.Clinical epigenetics · 2026Article
- Integrating cell-free DNA methylation of SEPT9 and SFRP2 into a machine learning model for early diagnosis of HCC.Biomarkers in medicine · 2025Article
- Development and clinical applications of liquid biopsy assays in cancer screening.Translational cancer research · 2025Review
- mSEPT9 performs better than CEA in NAT response and MRD assessment and recurrence prediction of stage III CRC.Biomarkers in medicine · 2025Article
- Colorectal cancer early screening: Dilemmas and solutions.World journal of gastroenterology · 2025Article
- Establishment and validation of predictive models by mutational and transcriptional factors for the prognosis of stage IV colorectal cancer patients with liver metastasis who undergo palliative surgery on primary tumors.Translational cancer research · 2025Article
- Multi-analyte liquid biopsy approaches for early detection of esophageal cancer: the expanding role of ctDNA.Frontiers in oncology · 2025Review
- Detection of a novel DNA methylation marker panel for esophageal cancer diagnosis using circulating tumor DNA.BMC cancer · 2024Article
- Comprehensive Multiomics Analyses Establish the Optimal Prognostic Model for Resectable Gastric Cancer : Prognosis Prediction for Resectable GC.Annals of surgical oncology · 2024Article
- DNA methylation biomarkers for early detection of gastric and colorectal cancers.Cancer biology & medicine · 2024Article
- DNA methylation markers in esophageal cancer.Frontiers in genetics · 2024Review
- Methylated SEPT9 assay-based liquid biopsy as a biomarker in molecular targeted agent-treated hepatocellular carcinoma.Hepatology international · 2023Article
- Methylated SEPT9 combined with AFP and PIVKA-II is effective for the detection of HCC in high-risk population.BMC gastroenterology · 2023Article
- The stoolTranslational cancer research · 2023Article
- Plasma-Methylated SEPT9 for the Noninvasive Diagnosis of Gastric Cancer.Journal of clinical medicine · 2022Article
- Methylated Septin9 (mCancer research communications · 2022Article
- Plasma Methylated RNF180 for Noninvasive Diagnosis of Gastric Cancer.BioMed research international · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe early detection of digestive cancers and precancerous diseases remains a significant challenge. This study aimed to investigate the performance of the blood methylated
methodsOpportunistic screening was performed in the participating hospitals on outpatients and inpatients who met specific inclusion criteria. We recruited a total of 2030 subjects, including 764 cancer patients [291 colorectal cancer (CRC), 239 gastric cancer (GC), 106 esophageal cancer (EC), and 128 hepatocellular carcinoma (HCC)], 423 subjects with precancerous diseases, and 843 normal subjects. All samples were transported to an authenticated clinical laboratory where the
resultsWhen used separately, the
conclusionThe blood
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.